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ABSTRACT
Introduction: Chronic asthma is a significant burden
for individual sufferers, adversely impacting their
quality of working and social life, as well as being a
major cost to the National Health Service (NHS).
Temperature-controlled laminar airflow (TLA) therapy
provides asthma patients at BTS/SIGN step 4/5 an add-
on treatment option that is non-invasive and has been
shown in clinical studies to improve quality of life for
patients with poorly controlled allergic asthma. The
objective of this study was to quantify the cost-
effectiveness of TLA (Airsonett AB) technology as an
add-on to standard asthma management drug therapy
in the UK.
Methods: The main performance measure of interest
is the incremental cost per quality-adjusted life year
(QALY) for patients using TLA in addition to usual care
versus usual care alone. The incremental cost of TLA
use is based on an observational clinical study
monitoring the incidence of exacerbations with
treatment valued using NHS cost data. The clinical
effectiveness, used to derive the incremental QALY
data, is based on a randomised double-blind placebo-
controlled clinical trial comprising participants with an
equivalent asthma condition.
Results: For a clinical cohort of asthma patients as a
whole, the incremental cost-effectiveness ratio (ICER)
is £8998 per QALY gained, that is, within the £20 000/
QALY cost-effectiveness benchmark used by the
National Institute for Health and Care Excellence
(NICE). Sensitivity analysis indicates that ICER values
range from £18 883/QALY for the least severe patients
through to TLA being dominant, that is, cost saving as
well as improving quality of life, for individuals with the
most severe and poorly controlled asthma.
Conclusions: Based on our results, Airsonett TLA is a
cost-effective addition to treatment options for stage 4/
5 patients. For high-risk individuals with more severe
and less well controlled asthma, the use of TLA
therapy to reduce incidence of hospitalisation would be
a cost saving to the NHS.
INTRODUCTION
The UK is considered to have one of the
highest prevalence rates of asthma in the
world, with an estimated 3–5.4 million
people in the UK living with asthma,1 of
whom 20% are children.2 Approximately
250 000 individuals continue to suffer severe
asthma symptoms and frequent exacerba-
tions inadequately controlled with available
medications.2 Emergency hospital admission
rates for acute asthma attacks are high, with
asthma in children constituting 20% of all
paediatric emergency admissions.
Chronic asthma adversely impacts patients’
quality of both working and social life, gener-
ating anxiety for family members and care
providers as well as being a major cost to the
nation. The National Health Service (NHS)
spends approximately £1 billion3 a year on
managing people with asthma.
Patients with severe asthma account for a
disproportionate share of the annual health-
care costs given more frequent exacerbations,
KEY MESSAGES
▸ Temperature-controlled laminar airflow (TLA)
therapy provides asthma patients at BTS/SIGN
stage 4/5 an add-on treatment option that is
non-invasive, and has been shown in clinical
studies to improve quality of life for patients
with poorly controlled allergic asthma.
▸ This study demonstrates that the incremental
cost-effectiveness ratio for TLA treatment with the
target patient group (individuals with moderate to
severe atopic asthma poorly controlled by stand-
ard medication), is £8998 per quality-adjusted life
year (QALY) gained, that is, within the £20 000/
QALY cost-effectiveness benchmark used by the
National Institute for Health and Care Excellence.
▸ Based on our results, TLA is a cost-effective add-
ition to treatment options for BTS/SIGN stage 4/5
patients. For high-risk individuals with more
severe and less well-controlled asthma, the use
of TLA therapy to reduce incidence of hospitalisa-
tion would be a cost saving to the NHS.
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and an overall higher use of the medical system. In add-
ition to the direct costs, indirect costs, those incurred by
patients, family, friends and other care providers,
amount to a signiﬁcant economic impact for society as a
whole. Asthma U.K. reports that 1.1 million working
days were lost due to breathing problems in 2008/2009.3
Asthma in children is a common cause of school
absence and, consequently, compromised education,
exam results, and therefore, lifetime career opportun-
ities and earnings. There remains an unmet medical
need for alternative and complementary approaches to
managing asthma that reduce exacerbations, increase
symptom control and provide patients with longer term
effective therapy.
The Temperature-controlled Laminar Airﬂow (TLA:
Airsonett AB) device is a non-pharmaceutical treatment
that delivers ﬁltered, allergen-free and particle-free air
to the patient’s breathing zone at night.4 5 It has been
shown in two placebo-controlled clinical trials and a
pragmatic study to be safe and effective in reducing
symptoms of asthma, including exacerbations and airway
inﬂammation, and to improve quality of life.6–8
TLA is targeted at patients with moderate to severe
perennial allergic asthma whose disease control is poor
despite compliance with recommended drug therapy.9
TLA is intended to complement or obviate the need
for use of expensive and/or potent drug therapies that
are associated with a greater risk of side effects.
However, in order for a novel therapeutic approach to
become accepted and recommended strategy, it is
necessary to not only demonstrate efﬁcacy but also cost
effectiveness.
The objective of this study was to quantify the health
economic value of TLA technology in the UK, based on
published evidence.
METHODS
The economic analysis is based on the medical resources
used by asthma patients participating in the clinical
study described in detail in the paper by Schauer et al.8
We evaluated the reported usage of health services for
all 30 clinical study participants on an intention-to-treat
basis for the 12 months pre-TLA and post-TLA adoption
using English health service costs to determine the
incremental cost of treatment.
For consistency with the Schauer study8 the economic
cost-effectiveness of TLA is initially calculated based on
the reported clinical outcomes. Sensitivity analysis of the
main economic drivers is then used to determine the
potential underestimate or overestimate of the cost-
effectiveness as initially calculated.
The incremental cost of treatment was then combined
with quality-of-life data acquired from the 1-year rando-
mised, double-blind, placebo-controlled, parallel-group
trial,7 to quantify the incremental cost-effectiveness ratio,
that is, incremental cost per quality-adjusted life year
(QALY) gained.
Clinical outcome observations
The Schauer study8 conducted in Germany, was a pre-
retrospective/post-retrospective observational study.
Patients with moderate to severe allergic asthma, uncon-
trolled despite pharmacological treatment, were
recruited. TLA was installed for 12 months, and data on
medication use, asthma control, asthma symptoms, lung
function, use of hospital resources and exacerbations
(deﬁned in accordance with the American Thoracic
Society/European Respiratory Society (ATS/ERS) deﬁn-
ition10) were collected at 4 and 12 months. Data
captured after installation of the TLA were analysed
and compared with corresponding data collected
retrospectively from medical records during the year
prior to inclusion in the study.
In total, 30 patients (mean age 28 years; range 8–
70 years) enrolled in the Schauer study.8 All 30 partici-
pants completed 4 months, and 27 patients completed
12 months of TLA use (3 patients failing to attend the
ﬁnal visit). The clinical and economic analysis includes
study participants on intention-to-treat basis, with the
last observation being carried forward for those complet-
ing at least 4 months with TLA.
When comparing the last 12 months pre-TLA, with the
consecutive 12 months of TLA use, the main clinical
observations8 were:
▸ The mean number of exacerbations was reduced
from 3.6 to 1.3 (p<0.0001);
▸ The ratio of study participants with asthma-related
emergency room visits or with hospitalisations dimin-
ished from 72.4% to 23.3% (p=0.001), and from
44.8% to 20.0% (p<0.05), respectively;
▸ No patient needed intensive care treatment after
TLA was introduced as compared with 14% during
the previous year, but this difference was not statistic-
ally signiﬁcant.
Both the placebo-controlled6 7 trials were powered to
show an effect on quality of life and not on exacerba-
tions. A post hoc analysis of the 1-year study results7
from those patients with an Asthma Control Test (ACT)
<18 in GINA stage 4 and >1 inhalant allergy was con-
ducted. They had signiﬁcantly fewer exacerbations on
active treatment compared with placebo (p=0.02),
(ﬁgure 1). These characteristics are similar to those in
the observational study.7
In summary, these studies demonstrated that the add-
ition of TLA to regular medication improved asthma
control, reduced the number of exacerbations, and con-
sequently, the usage of hospital resources declined. The
reduced burden on the health service is the economic
beneﬁt quantiﬁed in the ﬁnancial analysis.
Health service usage
Data collected prospectively from the 30 patients par-
ticipating in the Schauer study8 covered the
12 months of TLA use in terms of: emergency room
(accident and emergency, A&E) attendances, intensive
care unit (ICU) admissions or hospitalisations, that is,
2 Brazier P, Schauer U, Hamelmann E, et al. BMJ Open Resp Res 2016;3:e000117. doi:10.1136/bmjresp-2015-000117
Open Access
general admission. These were compared with corre-
sponding data (available for 29 patients) collected
retrospectively for the study baseline from medical
records at the hospitals or clinics where patients had
been treated during the prestudy year. The close align-
ment between German and UK asthma management
guidelines, and the consistent deﬁnition of exacerba-
tions enables the usage of medical resources observed in
the study to be valued in a UK context based on NHS
costs.
For the purposes of the economic analysis, a record in
the clinical study of a patient receiving inpatient treat-
ment is interpreted as ‘One hospital admission in
12 months’. This approach is conservative for quantify-
ing the economic savings as, in reality, patients may have
been admitted on more than one occasion.
The assumption is that all A&E, ICU and hospitalisa-
tion events occur as a result of asthma exacerbations. In
the majority of cases, the number of exacerbations
reported for a patient exceeds the aggregate number of
A&E, ICU and hospital visits reported. The incremental
exacerbations in these cases are presumed to have been
treated by a General Practitioner (GP) dispensing medi-
cation for the patient to self-administer at home, or the
patient increasing their medications following a self-
management action plan.
Two patients in the year prior to using Airsonett
reported three hospital episodes without exacerbations.
Two patients reported one hospital episode without
recording any exacerbation when using the TLA. In
each case the cost of the hospital episode has been
included in the economic analysis on the assumption
that the inpatient visit was asthma related.
The overall reduction in inpatient episodes during the
clinical study is presented in table 1.
The time a patient remains in hospital is a key driver
of treatment cost. For the two modes of admission, A&E
and general ward admission, the length of stay will vary
according to the patient’s needs, for example, A&E
admission is followed by discharge within 4 h, or hospital
admission, either for a short or long stay. Similarly, hos-
pitalisation via general ward admission may be for either
a short stay of up to 1 day or a long stay of more than
1 day.
Given that the target patient cohort of interest com-
prises individuals with more severe and less well-
controlled asthma, the assumptions are that: the major-
ity of patients (75%) admitted via A&E, and all patients
admitted via the ICU, will be transferred to a general
ward and remain in hospital for more than 1 day, that is,
a long-stay episode; likewise, the majority (75%) of
patients admitted directly to a general ward will remain
for a long-stay episode. The remaining patients, 25% of
A&E and 25% of general ward admissions are assumed
to be discharged within 1 day, that is, they are classiﬁed
as short stay.
Figure 1 Airsonett
temperature-controlled laminar
airflow (TLA) impact on
exacerbations, mean difference
and 95% confidence limits.
Table 1 Number of exacerbations and inpatient episodes reported
Exacerbations
Emergency
room visits
Intensive care
admissions
Hospital general
admissions
Outpatient
visits
12 Months prior to TLA 107 21 13 4 72
12 Months with TLA 39 7 6 0 28
Reduction 68 14 7 4 44
TLA, temperature-controlled laminar airflow.
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Cost of health services
A summary of the medical costs used to calculate the
total cost of treatment is presented in table 2.
Table 3 presents the total cost for each component of
health services resource use assuming
▸ That 50% of A&E and ICU and 10% of direct hos-
pital admission patients arrive by ambulance, at a cost
of an ambulance call-out of £235, that is, an average
cost per patient of £118 and £24, respectively.
▸ Patients admitted via ICU will remain in intensive
care for 42 h on average at a cost of £1168 per day,
that is, an average cost of £2044 per patient.
▸ Patients admitted via ICU are assumed to be dis-
charged from ICU to a high dependency unit
(HDU) for 24 h before being transferred to the
general ward at a cost of £852.
▸ Patients admitted via ICU are assumed to remain in a
general ward on average for 1.5 days (in addition to
the ICU and HDU) at a cost of £694 (ie, £462 per
day).
▸ Patients experiencing an asthma exacerbation visiting
a GP or outpatient clinic are assumed to be pre-
scribed standard rescue medication (£16), and the
cost of medical professionals attending the patient is
estimated at £54 given the need to monitor the
patient experiencing the asthma exacerbation until
the condition stabilises, that is, a total of £70 per visit.
▸ All patients are assumed to attend a follow-up GP
appointment within two working days, the national
standard of care,11 at a cost of £36.
The longest inpatient episode duration including ICU,
HDU and general ward of 4.25 days corresponds with
the observed duration of stay of 2 (1–5) days.12
The weighted average cost per patient admitted via
A&E or general ward (table 4) is based on the costs (see
table 3) and the assumed duration of stay mix (see
above). Costs for the ICU and GP/outpatient clinic
routes of admission are the sum of the costs for the indi-
vidual items of resource use applicable to those routes.
The derived average medical costs by mode of admis-
sion (table 4) are; A&E £1455, general ward £1090 and
ICU £3743 with a cost of £70 for treatment via out-
patient GP.
TLA cost
The reference TLA (Airsonett AB) cost to the NHS in
the UK is £2088 per patient for 12 months use. This cost
includes all maintenance/servicing, ﬁlter replacements,
and replacement with a new machine at the end of the
deemed lifetime of the device.
Quality-adjusted life years gained
Health-related quality-of-life was not an endpoint mea-
sured within the scope of the Schauer study.8 However,
in the prior 1-year placebo-controlled clinical trial com-
prising 312 asthmatics,7 the Mini Asthma Quality of Life
questionnaire (mini-AQLQ) and Paediatric Asthma
Quality of Life Questionnaire (PAQLQ) were completed.
The Swedish Institute for Health Economics (IHE)
used the mini-AQLQ data to derive ﬁve-dimensional
Asthma Quality of Life Questionnaire (AQLQ-5D) util-
ities and, thereby, QALY outcomes for the 235 (75%)
adult patient population13 using an algorithm developed
by Yang et al.14
The remaining 77 (25%) paediatric patients
(<12 years) completed the PAQLQ, which included
items similar in meaning for four of the ﬁve dimensions
of the AQLQ-5D. Data from patients who had com-
pleted both the mini-AQLQ and the PAQLQ were used
by the IHE to infer the AQLQ-5D outcomes, including
the outstanding ﬁfth dimension relating to air pollution,
for those who had completed only the PAQLQ. These
data were used to determine utilities, and thereby, QALY
outcomes for the paediatric population using the same
algorithm by Yang et al.14
A subgroup of 82 participants in the 1-year placebo-
controlled clinical trial7 were characterised as ACT <18
and GINA 4, that is, equivalent to the asthmatic condi-
tion of the Schauer study8 participants. The
quality-of-life outcome, using the individuals’ utility
values of this subgroup, is a statistically signiﬁcant 0.0615
utility improvement (p<0.0001),13 that is, a 0.0615 QALY
gain over a year. The 0.0615 utility gain is used for the
cost-effectiveness calculation presented below.
RESULTS
Economic cost-effectiveness
Table 5 summarises the cost-effectiveness calculations
where
Table 2 Health service resource costs
Health resources £ Source
Ambulance 235 per call out 1
A&E 115 per episode 2
Intensive care unit 1168 per day 3
High dependency unit 852 per day 2
Ward (admitted via A&E)
Short stay 584 up to 1 day 4
Long stay 1387 over 1 day 4
Ward (direct admission)
Short stay 523 up to 1 day 4
Long stay 1200 over 1 day 4
Ward average cost 462 per day 4
GP follow-up 36 per visit 1
GP/outpatient clinic 70 per visit 1
Sources:
1. PSSRU Unit costs of Health and Social Care 2013.
2. National schedule of reference costs 2012–13 for NHS Trusts
and NHS Foundation Trusts.
3. Hansard answer to a written question 2 September 2014,
20 653.
4. Average treatment costs based on a Hospital Episode Statistic
(HES data) sample of 426 episodes classified by HRG codes
D15F and PA12Z Optimity Advisors research.
A&E, accident and emergency; GP, general practitioner.
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▸ Total savings=cost per episode × reduction in epi-
sodes=£46 039
▸ Savings per person=total savings/30 study partici-
pants=£1535
▸ Incremental cost/(savings)=TLA (Airsonett) cost
(£2088—savings per person £1535)=£553
▸ Incremental cost-effective ratio (ICER)=incremental
cost (£553)/incremental QALY gain (0.0615)=£8998/
QALY.
Sensitivity analysis
The sensitivity analysis (table 6) evaluates the potential
impact of the underlying assumptions supporting the
economic model on the study’s ﬁndings and
conclusions.
The variables analysed are as follows:
1. Treatment costs: Substitution of inpatient A&E and
rates of hospitalisation costs used above with the fol-
lowing reference costs; National Reference Costs by
Service Description 2012/13, Reimbursement Tariff
for DRG codes DZ15F and PA12Z, and National
Reference Spell Cost Data 2012/13. Results indicate
that TLA remains cost-effective with ICER values of
£11 170, £15 108 and £6515 per QALY, respectively.
2. Severity of condition: The severity of the patient’s condi-
tion on arrival at hospital determines the degree of
medical attention a patient receives, and their rate of
recovery determines their duration of hospital stay;
both factors impact the healthcare resources
required, and thus, treatment cost.
TLA is targeted for patients with severe uncontrolled
perennial allergic asthma, thus, the actual cost to the
health service would be greater than the average cost of
treatment of patients classiﬁed by DRG codes DZ15F
and PA12Z.
To illustrate the variation in treatment costs, the ana-
lysis ranks the total actual episode cost per patient from
highest to lowest, segregates into quartiles, and calcu-
lates the net cost and cost-effectiveness using the average
cost by quartile.
The analyses indicate that valuing the cost of treat-
ment based on the highest cost rates delivers the greatest
savings, that is, largest cost reduction, and results in the
use of TLA being dominant, that is, cost saving while
improving the patient’s utility. Treatment costs based on
the lowest cost rates results in TLA being cost-effective at
an ICER of £15 829/QALY.
3. Inpatient events: Participants in the Schauer study8
recorded if they had ‘At least one’ A&E, ICU or hos-
pital visit in the year prior to, or the year following,
TLA use.
In the absence of more detailed information, the most
conservative interpretation of ‘At least once’ is exactly
one inpatient admission. Given that the patient cohort
was speciﬁcally selected to comprise the more severe
and less controlled asthma patients, it is likely that some
patients would have experienced more than one A&E,
ICU or hospital visit during each year in question, par-
ticularly for patients with multiple exacerbations.
Of the eight patients who reported just one exacerba-
tion, these also reported inpatient admission on six of
those occasions, that is, a 75% admission rate. Patients
who reported three or fewer exacerbations were admit-
ted as inpatients for 73% of their exacerbations.
However, patients reporting four or more exacerbations
were admitted for only 22% of their exacerbations. The
low admission rate for patients with more frequent
exacerbations is likely to be attributable to the under-
reporting, there is no clinical reason why people with
more frequent exacerbations should be admitted to hos-
pital less often.
Table 3 Total treatment costs by mode of hospital admission
Patient pathway
Ambulance
(£) A&E (£) ICU (£) HDU (£)
Ward short
stay (£)
Ward long
stay (£)
GP outpatient
(£) Total (£)
(A) A&E
A1 118 115 36 269
A2 118 115 584 36 852
A3 118 115 1387 36 1656
(B) Hospitalisation
B1 24 523 36 583
B2 24 1200 36 1259
(C) Intensive Care 118 2044 852 694 36 3743
(D) GP/outpatient clinic 70 70
A&E, accident and emergency; GP, general practitioner; HDU, high dependency unit; ICU, intensive care unit.
Table 4 Weighted average cost by treatment pathway
Patient pathway
Total
cost (£)
Patient
mix (%)
Weighted
average (£)
(A) Emergency room 1455
A1 269 0
A2 852 25
A3 1656 75
(B) Hospitalisation 1090
B1 583 25
B2 1259 75
(C) Intensive care 3743 100 3743
(D) General practitioner 70 100 70
Brazier P, Schauer U, Hamelmann E, et al. BMJ Open Resp Res 2016;3:e000117. doi:10.1136/bmjresp-2015-000117 5
Open Access
The sensitivity analysis assumes that patients reporting
four or more exacerbations in a year who were admitted
to hospital did so for 50% (rather than 22%) of their
exacerbations. This results in the use of TLA being
dominant.
4. Length of inpatient stay: The shorter the length of
stay the lower the treatment costs, and the lower are
cost savings using TLA. Under the following two
scenarios, ﬁrst, only half the patients admitted via
A&E or a general ward remained for a long stay,
with half discharged the same day or, second,
patients admitted via A&E are discharged within 4 h
(one-third), hospitalised for a short stay (one-third),
or hospitalised for a long stay (one-third); the result-
ing ICERs are £11 163/QALY and £13 656/QALY,
respectively, that is, the use of TLA remains
cost-effective.
5. Intention to treat: Of the 30 participants in the clinical
study, all completed 4 months use of TLA, and 27
completed the full 12 months. To test the economic
impact of using the last observation carried forward
for the three individuals who did not complete the
full 12 months with TLA, the 4-month exacerbation
and frequency of inpatient admission for these parti-
cipants were extrapolated at the observed rate over
the full 12 months. The resulting ICER under this
scenario was £10 400/QALY. While this ICER value is
higher than the base case £8998/QALY the differ-
ence does not impact the overall conclusions drawn
from the economic analysis.
6. Incidence of inpatient admissions without reported exacerba-
tions: Elimination of inpatient admissions where no
corresponding exacerbations had been reported
results in an ICER of £9588/QALY, the increase
being immaterial to the overall conclusion.
7. QALY value: A change in QALY gain results in an
inversely proportional change to the ICER outcome.
A 55% decrease in the QALY to 0.0277 is required to
generate an ICER of £20 000/QALY, the cost-
effectiveness threshold. A similar increase of 55% in
the QALY to 0.0953 reduces the ICER to £5800.
Uncertainties associated with the QALY value calcula-
tion are not anticipated to result in this order of mag-
nitude variation, hence, are not anticipated to impact
the overall conclusion regarding the cost-effectiveness
of TLA.
Table 5 Cost-effectiveness calculation
A&E ICU Hospitalisation Outpatient
12 Months prior to TLA 21 4 13 72
12 Months with TLA 7 0 6 28
Reduction 14 4 7 44
Cost per episode £1455 £3743 £1090 £70
Total
Total savings £20 367 £14 973 £7630 £3069 £46 039
Savings per person £1535
Incremental cost/(savings) £553
Incremental cost-effective ratio £8998/QALY
A&E, accident and emergency; ICU, intensive care unit; QUALY, quality-adjusted life years; TLA, temperature-controlled laminar airflow.
Table 6 Sensitivity analysis
Sensitivity variable
Net cost
(saving)
£ pp/pa
ICER
£/QALY
Base case 553 8998
1. Treatment costs
National reference costs by
service description 2012/13
687 11 170
Reimbursement tariff 2014/15 929 15 108
National reference costs spell
data 2012/13
401 6515
2. Severity of condition
Top quartile by treatment cost
per episode
(151) Dominant
Second quartile by treatment
cost per episode
524 8527
Third quartile by treatment cost
per episode
822 13 365
Bottom quartile by treatment cost
per episode
973 15 829
3. Inpatient events
Increased inpatient visit
frequency
(142) Dominant
4. Length of inpatient stay
Pathway mix long: short stay
50:50
687 11 163
Pathway mix include discharge
from A&E
840 13 656
5. Intention to treat 640 10 400
6. Incidence of inpatient
admissions without reported
exacerbation
590 9588
7. QALY value
55% increase in QALY 553 5800
55% decrease in QALY 553 20 000
8. ‘Least cost-effective’ scenario 1161 18 883
A&E, accident and emergency; ICER, incremental
cost-effectiveness ratio; pp aa, per patient per annum; QUALY,
quality-adjusted life year.
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8. The ‘Least cost-effective’ scenario: This is the combination
of economic characteristics giving the highest cost-
effectiveness ratio (assuming a QALY outcome of
0.0615) includes
▸ The reimbursement Tariff 2014/15 with
▸ One of 3 patients discharged from A&E, 1/3 short
stay and 1/3 long stay
▸ The extrapolation of the data for three patients
from month 4 to month 12
▸ No inpatient events reported in the absence of an
exacerbation.
The resulting ICER is £18 833, within the £20 000/
QALY threshold.
The sensitivity analysis indicates that the three most sig-
niﬁcant factors that impact the cost-effectiveness of TLA
treatment are:
▸ ICU admissions. Patient admission via ICU followed
by additional time in HDU is the most expensive clin-
ical pathway, at £3738 per episode of 4.25 days in
hospital.
▸ The cost base used for the valuation of health ser-
vices. There is a notable difference between the HES
data and National Reference cost for long-term
inpatient treatment (ie, in excess of £1000 per
patient episode) and the corresponding
Reimbursement Tariff for reimbursement, that is,
£630 per patient episode. The resulting ICER values
using the three cost sources are £9998, £11 170, and
£15 108, respectively (table 6).
▸ Actual costs incurred for the provision of care are
best represented by the local NHS Trust cost, that is,
HES data, or the National Reference Costs at an
overall NHS level. From the perspective of commis-
sioning health service, using the Reimbursement
Tariff to value TLA therapy results in a less cost-
effective outcome, but signiﬁcantly remaining below
the £20 000/QALY threshold.
DISCUSSION
TLA therapy is intended for use as an add-on therapy by
patients with perennial allergic asthma whose disease
control is poor despite compliance with recommended
therapy, that is, corresponding to step 4 (GINA; BTS), as
represented by the participants in the Schauer study.8
The current study demonstrates the value of preventing
exacerbations from the perspective of both the well-
being of the patient and the economic advantage to the
NHS arising from the reduced burden on health
services.
Life-time cost-effectiveness cannot be accurately
assessed for any asthma treatment given too many vari-
ables including, the natural history of the condition,
treatment compliance, changes in allergen exposures,
frequency of rhinovirus infections, and side effects of
treatment. We believe that TLA, by reducing particulate
allergen exposure over long periods, is more likely to
alter the long-term outcomes beneﬁcially. However, we
consider it inappropriate in the absence of long-term
trials to make such assumptions.
Given the signiﬁcant burden of uncontrolled asthma,
TLA as a treatment option that provides short-term clin-
ical and economic beneﬁts, is of interest to patients and
society. The current economic analysis considers the
cost-effectiveness of over 1 year of treatment deemed to
be the minimum time needed to capture seasonal
variations.
The Schauer study8 is a precomparison and postcom-
parison of TLA use, with patients serving as their own
control. The data quality of retrospective studies relies
very much on the accuracy and completeness of the clin-
ical records. Incomplete data may have been obtained
from patient records during the pre-TLA period leading
to an underestimation of usage of hospital resources,
compared with the TLA period consequently an under-
estimate of savings.
As there was no control group, spontaneous improve-
ments in medical morbidity would not be identiﬁed.
While not quantiﬁable, this is considered a low risk.
Adherence to treatment may have improved during
the observation period of TLA use; the risk of bias was
considered minimal given that patients selected had a
history of good compliance with treatment. Eligible
patients had a considerable disease burden for several
years, making previous non-adherence to treatment
unlikely.
From an economic perspective, the valuation of
usage of health resources pre-TLA and post-TLA adop-
tion were based on a common set of health service
resource costs to eliminate any introduction of eco-
nomic bias, and to neutralise the possible impact of
inﬂation.
A degree of uncertainty arises from the QALY calcula-
tion. In the absence of quality-of-life data directly avail-
able from the Schauer study,8 QALYs were derived from
participants in the clinical study7 with common
characteristics of asthma. The QALY calculations are
derived from AQL-5D values, which in the majority of
cases are obtained directly from answers to the
mini-AQLQ and/or PAQLQ, with good reliability.
However, the degree of uncertainty associated with the
QALY calculation is not considered material to the
overall conclusion regarding the cost-effectiveness of
TLA.
From the Schauer study,8 economic savings in direct
NHS medical costs is estimated at £1535 per patient per
annum (pp pa). This saving is offset by the TLA cost of
£2088 pp pa resulting in a net cost of £553 pp pa to the
NHS. The resulting ICER is £8998, that is, it is less than
half the £20 000/QALY threshold considered as the
acceptable cost-effectiveness benchmark used by the
National Institute for Health and Care Excellence.
There is a positive correlation between severity of con-
dition and poor asthma control, and the economic
burden to the health service with the most severe cases
accounting for a disproportionately large share of both
Brazier P, Schauer U, Hamelmann E, et al. BMJ Open Resp Res 2016;3:e000117. doi:10.1136/bmjresp-2015-000117 7
Open Access
direct and indirect healthcare costs (ie, lost time at
work and education).15 For certain high-risk individuals,
with more severe and less well-controlled asthma, avoid-
ance of two hospital admissions (via A&E or general
admission), or one ICU admission per year, would
result in the TLA therapy being a cost saving to the
NHS.
The economic value of TLA as presented, is likely to
be understated due to the prudent interpretation of
inpatient episodes from the clinical study, that is, a
maximum of one inpatient episode by mode of hospital
admission irrespective of the number of exacerbations
reported. Increasing the assumed frequency of inpatient
visits per exacerbation would result in TLA being more
cost-effective and potentially cost saving.
Improved asthma control provides additional economic
and clinical beneﬁts, for example:
▸ The patient’s rate of recovery, and hence, duration of
hospital stay is a key cost driver of actual costs
incurred by the NHS. Improved asthma control,
through TLA use, may result in less intensive care or
shorter inpatient stay when treating an exacerbation.
▸ Reduced use of rescue medication.
▸ Less absenteeism from work or education for the
individual patient, family and care providers.
▸ Decreasing the incidence of asthma exacerbations
improves lung function, thereby, particularly for chil-
dren, reducing the risk of developing persistent
severe asthma.16
The analysis in this study has shown that TLA provides
asthma patients a treatment option that is non-invasive,
with demonstrable health and economic beneﬁts. These
ﬁndings are consistent with previous studies demonstrat-
ing the economic and clinical value of TLA treatment
for asthma sufferers.13 17–19
Our primary analysis of cost is based on one uncon-
trolled observational study, and a large placebo-
controlled trial to derive the ICER. Our health eco-
nomic evaluation also uses a number of assumptions,
namely, that the pathways of care in Germany are similar
to those in the UK, and extrapolates healthcare costs
based on UK national averages.
Clearly, a placebo-controlled trial powered to detect
an effect on exacerbations will provide the ultimate con-
ﬁrmation of cost-effectiveness, and such a study is now
in progress: Laminar Airﬂow in Severe Asthma for
Exacerbation Reduction (LASER).20
However, we believe, that based on our results,
Airsonett TLA provides a cost-effective additional option
for the treatment of BTS/SIGN stage 4/5 patients.
Further studies into the long-term outcomes of TLA
therapy would provide valuable clinical and economic
insights.
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